ALNY vs RPRX
Alnylam Pharmaceuticals, Inc. and Royalty Pharma plc, both Healthcare
Alnylam Pharmaceuticals, Inc. is the larger company at $39B against $31B. On trailing earnings RPRX is the cheaper of the two at a P/E of 30.3 against 118.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year RPRX returned +59% against -49% for ALNY. The RyuScore puts RPRX ahead, 52 against 15 out of 100.
| Figure | ALNY | RPRX |
|---|---|---|
| Last close | $233 | $56.90 |
| Market cap | $39B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 118.1 | 30.3 |
| 1-year return | -49% | +59% |
| 5-year return | +24% | +61% |
| RyuScoresector-relative, 1–10 | 15/100 | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 67% of the disclosed total.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.